<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">POLYCARBOPHIL</span><br/>(pol-i-kar'boe-fil)<br/><span class="topboxtradename">Equalactin, </span><span class="topboxtradename">FiberNorm<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">bulk laxative</span>; <span class="classification">antidiarrheal</span><br/><b>Prototype: </b>Psyllium<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 625 mg tablets; 500 mg, 625 mg chewable tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Hydrophilic agent which absorbs free water in intestinal tract and opposes dehydrating forces of bowel by forming a gelatinous
         mass.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Restores more normal moisture level and motility in the lower GI tract; produces well-formed stool and reduces diarrhea.</p>
<h1><a name="uses">Uses</a></h1>
<p>Constipation or diarrhea associated with acute bowel syndrome, diverticulosis, irritable bowel and in patients who should
         not strain during defecation. Also choleretic diarrhea, diarrhea caused by small-bowel surgery or vagotomy, and disease of
         terminal ileum.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Partial or complete GI obstruction; fecal impaction; dysphagia; acute abdominal pain; rectal bleeding; undiagnosed abdominal
         pain, or other symptoms symptomatic of appendicitis; poisonings; before radiologic bowel examination; bowel surgery. Safety
         in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Constipation or Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 g q.i.d. prn (max: 6 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>36 y,</i> 500 mg b.i.d. prn (max: 1.5 g/d); <i>612 y,</i> 500 mg t.i.d. prn (max: 3 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Chewable tablets should be chewed well before swallowing.</li>
<li>Give each dose with a full glass [240 mL (8 oz)] of water or other liquid.</li>
<li>Repeat dose every 30 min up to the maximum dose in 24 h with severe diarrhea.</li>
<li>Store at 15°30° C (59°86° F) in tightly closed container unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Esophageal blockage, intestinal impaction, <span class="speceff-common">abdominal fullness.</span>
<span class="typehead">Metabolic:</span> Low serum potassium, elevated blood glucose levels (with extended use). <span class="typehead">Respiratory:</span> Asthma. <span class="typehead">Skin:</span> Skin rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease absorption and clinical effects of <span class="classification">antibiotics</span>, <b>warfarin,</b>
<b>digoxin,</b>
<b>nitrofurantoin,</b>
<span class="classification">salicylates</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Not absorbed from GI tract. <span class="typehead">Onset:</span> 1224 h. <span class="typehead">Peak:</span> 13 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine duration and severity of diarrhea in order to anticipate signs of fluid-electrolyte losses.</li>
<li>Monitor and record number and consistency of stools per day, presence and location of abdominal discomfort (i.e., tenderness,
            distension), and bowel sounds.
         </li>
<li>Monitor and record I&amp;O ratio and pattern. Dehydration is indicated if output is 
         </li><li>Inspect oral cavity for dryness, and be alert to systemic signs of dehydration (e.g., thirst and fever). Dehydration from
            an episode of diarrhea appears rapidly in young children and older adults.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Consult physician if sudden changes in bowel habit persist more than 1 wk, action is minimal or ineffective for 1 wk, or if
            there is no antidiarrheal action within 2 d.
         </li>
<li>Be aware that extended use of this drug may cause dependence for normal bowel function.</li>
<li>Do not discontinue polycarbophil unless physician advises if also taking an oral anticoagulant, digoxin, salicylates, or nitrofurantoin.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>